Seasoned Politician, Rebellious Journalist Saleh Al-Qallab Passes Away

Saleh Al-Qallab (Asharq Al-Awsat)
Saleh Al-Qallab (Asharq Al-Awsat)
TT

Seasoned Politician, Rebellious Journalist Saleh Al-Qallab Passes Away

Saleh Al-Qallab (Asharq Al-Awsat)
Saleh Al-Qallab (Asharq Al-Awsat)

Asharq Al-Awsat, on Wednesday, lost one of its prominent writers with the passing of the former Jordanian minister and journalist, Saleh Al-Qallab. He endured a long and courageous battle against illness, standing firm in the face of it until his last breath.

Al-Qallab, born in 1944 in the eastern Jordanian province of Mafraq, led a life that took him to various capitals around the world.

However, he never wavered in his steadfastness to his principles.

He was known for his amicable nature, even with his political adversaries, and for his impassioned dedication to his journalistic work in positions of responsibility.

Whether he was a television commentator, a minister in challenging circumstances, or a member of the Jordanian Senate, he remained resolute.

Al-Qallab had a socialist upbringing and political career.

After his incomplete studies at the University of Jordan due to his affiliation with the Ba’ath Party, he left Jordan for Syria following his release from prison.

However, his stay in Damascus was short-lived, as he disassociated himself from the Ba’ath Party after the corrective movement led by the late President Hafez Al-Assad.

He then moved to Beirut, where he aligned himself with the Fatah movement and grew close to its late leader, Yasser Arafat.

Throughout the 1970s, Al-Qallab worked for Lebanese newspapers and news agencies before leaving Beirut following the Israeli invasion of Lebanon in 1982.

The democratic transition initiated by Jordan’s late King Hussein in 1989 marked a new chapter in Al-Qallab’s life, one in which he reconciled with former adversaries.

He later served as the Minister of Information in two different governments.

After leaving his government position, he maintained his seat in the Senate and continued to contribute as a writer for both the Jordanian newspaper “Al-Rai” and Asharq Al-Awsat.

 

 



Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
TT

Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights

Women’s heart disease risks and their need to start taking preventive medications should be evaluated when they are in their 30s rather than well after menopause as is now the practice, said researchers who published a study on Saturday.

Presenting the findings at the European Society of Cardiology annual meeting in London, they said the study showed for the first time that simple blood tests make it possible to estimate a woman’s risk of cardiovascular disease over the next three decades.

"This is good for patients first and foremost, but it is also important information for (manufacturers of) cholesterol lowering drugs, anti-inflammatory drugs, and lipoprotein(a)lowering drugs - the implications for therapy are broad," said study leader Dr. Paul Ridker of Brigham and Women’s Hospital in Boston, Reuters reported.

Current guidelines “suggest to physicians that women should generally not be considered for preventive therapies until their 60s and 70s. These new data... clearly demonstrate that our guidelines need to change,” Ridker said. “We must move beyond discussions of 5 or 10 year risk."

The 27,939 participants in the long-term Women’s Health Initiative study had blood tests between 1992 and 1995 for low density lipoprotein cholesterol (LDL-C or “bad cholesterol”), which are already a part of routine care.

They also had tests for high-sensitivity C-reactive protein (hsCRP) - a marker of blood vessel inflammation - and lipoprotein(a), a genetically determined type of fat.

Compared to risks in women with the lowest levels of each marker, risks for major cardiovascular events like heart attacks or strokes over the next 30 years were 36% higher in women with the highest levels of LDL-C, 70% higher in women with the highest levels of hsCRP, and 33% higher in those with the highest levels of lipoprotein(a).

Women in whom all three markers were in the highest range were 2.6 times more likely to have a major cardiovascular event and 3.7 times more likely to have a stroke over the next three decades, according to a report of the study in The New England Journal of Medicine published to coincide with the presentation at the meeting.

“The three biomarkers are fully independent of each other and tell us about different biologic issues each individual woman faces,” Ridker said.

“The therapies we might use in response to an elevation in each biomarker are markedly different, and physicians can now specifically target the individual person’s biologic problem.”

While drugs that lower LDL-C and hsCRP are widely available - including statins and certain pills for high blood pressure and heart failure - drugs that reduce lipoprotein(a) levels are still in development by companies, including Novartis , Amgen , Eli Lilly and London-based Silence Therapeutics.

In some cases, lifestyle changes such as exercising and quitting smoking can be helpful.

Most of the women in the study were white Americans, but the findings would likely “have even greater impact among Black and Hispanic women for whom there is even a higher prevalence of undetected and untreated inflammation,” Ridker said.

“This is a global problem,” he added. “We need universal screening for hsCRP ... and for lipoprotein(a), just as we already have universal screening for cholesterol.”